Twist Bioscience, in partnership with clinical sequencing services provider CeGaT, has introduced the Twist Alliance CeGaT RNA Fusion Panel for accelerating research in oncology and precision medicine.

The fusion panel is intended to identify ribonucleic acid (RNA) fusions and carry out analysis of transcript variants for oncology research.

The panel comprises more than 150 fusion genes and integrates Twist’s RNA Library Prep and fusion capture with CeGaT’s software analysis to identify fusion events in specific tumour types and detect new fusion events.

CeGaT managing director and co-founder Dr Dirk Biskup said: “We combined Twist’s RNA Library Prep and target enrichment capabilities with our expert knowledge in tumour diagnostics and panel design.

“This is how together we created the Twist Alliance CeGaT RNA Fusion Panel enriching for over 150 fusion genes. This panel is designed to deliver high-quality results, even from low-input samples.”

Twist Bioscience CEO and co-founder Dr Emily Leproust said: “As we expand into the RNA market, the Twist Alliance CeGaT RNA Fusion Panel adds to our growing RNA sequencing toolset, which includes the Twist RNA Exome, RNA Library Prep and rRNA and Globin Depletion Kit.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It also adds to our growing portfolio of DNA and RNA products that could be used to support precision medicine research in oncology.”

Twist Bioscience worked with major research institutions to develop target enrichment panels for research applications such as carrier screening, whole exome sequencing and cancer identification.